Acular LS and Fedratinib Hydrochloride
Determining the interaction of Acular LS and Fedratinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation. MANAGEMENT: Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. References "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA. "Product Information. Xibrom (bromfenac ophthalmic)." ISTA Pharmaceuticals, Irvine, CA. "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
Professional:MONITOR: Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.
MANAGEMENT: Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA.
- "Product Information. Xibrom (bromfenac ophthalmic)." ISTA Pharmaceuticals, Irvine, CA.
- "Product Information. Nevanac (nepafenac ophthalmic)." Alcon Laboratories Inc, Fort Worth, TX.
Generic Name: ketorolac ophthalmic
Brand name: Acular, Acular LS, Acuvail, Acular PF
Synonyms: n.a.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Acular LS-Feiba
- Acular LS-Feiba NF
- Acular LS-Feiba VH Immuno
- Acular LS-Feiba-VH
- Acular LS-Felbamate
- Acular LS-Felbamate Oral Suspension
- Fedratinib Hydrochloride-Acular PF
- Fedratinib Hydrochloride-Acunivive 15 Injection System
- Fedratinib Hydrochloride-Acunivive 30 Injection System
- Fedratinib Hydrochloride-Acunivive 60 Injection System
- Fedratinib Hydrochloride-Acunivive 90 Injection System
- Fedratinib Hydrochloride-Acuvail